Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07423481 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity

Study acronym: SEMAFOLLOW
StatusNot Yet Recruiting
PhaseNot specified
Started2026-10-01
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 4 months later Mar 1, 2027 → Jul 1, 2027
See other at-risk trials from Nantes University Hospital

Amendment history

2026-09-19
Primary completion pushed: 2027-03-01 → 2027-07-01
Completion pushed: 2027-03-01 → 2027-07-01
2026-05-11
Study Status v2
Re-verified, no change to tracked fields
2026-02-24
Study Status, Outcome Measures v1
Secondary endpointsdetails revised at 3 of 3 entries
2026-02-13
Original filing
SEMAFOLLOW is a real-world follow-up study examining the outcomes of individuals treated with WEGOVY® (semaglutide 2.4 mg) under the temporary authorisation for use (ATU) and early access programme in France. This study evaluates weight change, treatment strategies and well-being, drawing on the expertise of teams from various specialist obesity centres in France.
Trial Details
NCT Number NCT07423481
Lead Sponsor Nantes University Hospital
Collaborators: Novo Nordisk A/S
Conditions Obesity & Overweight
Enrollment 3,000 participants
Start Date 2026-10-01
Primary Completion 2027-07-01 (estimated)
Study Completion 2027-07-01 (estimated)
Updated on ClinicalTrials.gov 2026-09-18